Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer
Journal of Medicinal Chemistry · 25.06.2026 · 69 (12) · 14437-14460
DOI: 10.1021/acs.jmedchem.6c00196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.06.2026. Verfasst von Xingchen Liu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: SOS1 Protein, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, National Natural Science Foundation of China, Sichuan Provincial Special Program for Leading Scientists in Basic Research.
Abstract (Originalsprache)
The guanine nucleotide exchange factor SOS1 has emerged as an attractive therapeutic target for various KRAS-driven tumors. Herein, we employed a structure-based drug design strategy to develop a series of novel quinazoline-derived molecules. This effort yielded highly potent and selective SOS1 inhibitors, 78b and 78d, which displayed high SOS1 binding affinity, potently disrupted the SOS1-KRASG12C interaction, and inhibited nucleotide exchange in WT and multiple KRAS variants. Moreover, both compounds showed submicromolar 3D-antiproliferative activity across a panel of CRC cells, induced G1 phase arrest, and suppressed MAPK and PI3K signaling pathways. Furthermore, 78b and 78d demonstrated favorable safety profiles with no observed adverse effects at levels of 500 and 700 mg/kg, respectively. At doses of 60 mg/kg, they achieved significant tumor growth inhibition (75.1% and 86.2%, respectively) in HCT116 xenograft models without significant toxicity. Collectively, this study identifies potent drug candidates with strong pan-KRAS therapeutic efficacy against colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- National Clinical Research Center for Geriatrics, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 61004, China.
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Green Pharmaceutical Technology Key Laboratory of Luzhou City, Central Nervous System Drug Key Laboratory of Sichuan Province, Department of Medicinal Chemistry, School of Pharmacy, Southwest Medical University, Luzhou…
- National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Jinhua Zhao, Xia Zhou, Youfu Luo, Yinglan Zhao
Förderung
- West China Hospital, Sichuan University
- National Natural Science Foundation of China
- Sichuan Provincial Special Program for Leading Scientists in Basic Research
Zitieren
APA
Liu, X., Xiao, Y., Zhou, Y., Teng, Y., Zou, J., Zhou, Y., Fan, X., Zhao, J., Qiu, J., Tang, L., Qiu, Z., Xu, J., Luo, H., Pan, X., Xu, W., Ren, B., Gou, K., Liu, C., Ren, Y., …, & Zhao, Y. (2026). Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of Medicinal Chemistry, 69(12), 14437-14460. https://doi.org/10.1021/acs.jmedchem.6c00196
Vancouver
Liu X, Xiao Y, Zhou Y, Teng Y, Zou J, Zhou Y, et al. Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of Medicinal Chemistry. 2026;69(12):14437-14460. doi:10.1021/acs.jmedchem.6c00196
BibTeX
@article{Liu2026,
author = {Liu, Xingchen and Xiao, Yuzhou and Zhou, Yanmei and Teng, Yaxin and Zou, Jiao and Zhou, Yue and Fan, Xinyu and Zhao, Jinhua and Qiu, Jiahao and Tang, Lingfeng and Qiu, Zhiqiang and Xu, Jing and Luo, Haoyue and Pan, Xiaodan and Xu, Wenjing and Ren, Bo and Gou, Kun and Liu, Chunqi and Ren, Yanyan and Song, Jialing and Gao, Ping and Zhou, Xia and Zhang, Laiying and Qian, Xinying and Lei, Jian and Cen, Xiaobo and Luo, Youfu and Zhao, Yinglan},
title = {Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {12},
pages = {14437--14460},
doi = {10.1021/acs.jmedchem.6c00196}
}
EUVIMED